Verve Therapeutics Ratios and Metrics

Market cap in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	Current	FY 2024	FY 2023	FY 2022	FY 2021	FY 2009	2019 - 2020
Period Ending	Aug '25 Aug 6, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '09 Dec 31, 2009	2019 - 2020
Market Capitalization	58	71	4,332	-	-	-	Upgrade
Market Cap Growth	-70.30%	-98.37%	-	-	-	-	Upgrade
Enterprise Value	57	74	4,334	-	-	-	Upgrade
Last Close Price	5.29	33.57	582.50	531.00	491.00	-	Upgrade
PS Ratio	0.08	3.23	210.46	-	-	-	Upgrade
PB Ratio	-	-15.22	-1105.76	-	-	-	Upgrade
EV/Sales Ratio	2.57	3.40	210.53	-	-	-	Upgrade
Debt / Equity Ratio	-2.22	-1.96	-2.36	-1.26	-1.14	-	Upgrade
Debt / EBITDA Ratio	-	-	-	5.47	0.56	-	Upgrade
Debt / FCF Ratio	-	-	-	5.78	0.80	-	Upgrade
Asset Turnover	1.23	1.33	1.36	1.37	-	-	Upgrade
Inventory Turnover	2.47	3.57	4.03	3.81	-	-	Upgrade
Quick Ratio	0.66	0.78	0.77	1.54	2.25	43.07	Upgrade
Current Ratio	1.00	0.94	1.19	1.85	2.68	44.97	Upgrade
Return on Assets (ROA)	-8.27%	-7.99%	-35.66%	3.11%	-	-	Upgrade
Return on Capital (ROIC)	-32.21%	-26.79%	-173.49%	67.62%	-	-	Upgrade
Return on Capital Employed (ROCE)	-	-	-	10.20%	66.70%	-	Upgrade
Earnings Yield	-17.67%	-12.46%	-0.24%	-	-	-	Upgrade
FCF Yield	-11.96%	-5.71%	-0.14%	-	-	-	Upgrade
Payout Ratio	-	-	-	-	6.67%	-	Upgrade
Buyback Yield / Dilution	82.14%	-38.41%	97.46%	-	-	-	Upgrade

Updated Nov 14, 2024. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q